rs4143815-<i>PDL1</i>, a New Potential Immunogenetic Biomarker of Biochemical Recurrence in Locally Advanced Prostate Cancer after Radiotherapy

rs4143815-<i>PDL1</i>, a New Potential Immunogenetic Biomarker of Biochemical Recurrence in Locally Advanced Prostate Cancer after Radiotherapy

Up to 30&#8722;50% of patients with locally advanced prostate cancer (PCa) undergoing radiotherapy (RT) experience biochemical recurrence (BCR). The immune system affects the RT response. Immunogenetics could define new biomarkers for personalization of PCa patients&#8217; treatment. The aim...

Full description

Bibliographic Details
Main Authors: Chiara Zanusso, Eva Dreussi, Roberto Bortolus, Chiara Romualdi, Sara Gagno, Elena De Mattia, Loredana Romanato, Franca Sartor, Luca Quartuccio, Erika Cecchin, Giuseppe Toffoli
Format: Article
Language:English
Published: MDPI AG 2019-04-01
Series:International Journal of Molecular Sciences
Subjects:
prostate cancer
immunogenetics
biomarker
radiotherapy
biochemical recurrence
Online Access:https://www.mdpi.com/1422-0067/20/9/2082

Similar Items

Similar Items